


A Major Biosimilar Monoclonal Antibodies Market Driver Is The Prevalence Of Chronic Diseases

The Business Research Company's Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, April 30, 2021 /EINPresswire.com/ -- Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: <https://www.thebusinessresearchcompany.com/global-market-reports>



The prevalence of chronic diseases is expected to drive the [biosimilar monoclonal antibodies market](#). Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune disease, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. According to the American cancer society (ACS), in 2020, about 1.8 million new cancer cases are expected in the United States. Therefore, the prevalence of chronic diseases including cancer is expected to drive the biosimilar monoclonal antibodies market.

The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease. Biosimilar monoclonal antibodies are highly similar to actual monoclonal antibodies in terms of pharmaceutical quality, safety, and efficacy, and are used to boost immunity by identifying and neutralizing foreign bodies. The market consists of revenue generated by the biosimilar monoclonal antibodies companies by the sales of these products.

Read More On The Global Biosimilar Monoclonal Antibodies Market Report:

<https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodies-global->

[market-report-2020-30-covid-19-growth-and-change](#)

The global biosimilar monoclonal antibodies market is expected to grow from \$3.52 billion in 2020 to \$4.33 billion in 2021 at a compound annual growth rate (CAGR) of 23%. The biosimilar antibodies market growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The MABs biosimilars market size is expected to reach \$10.92 billion in 2025 at a CAGR of 26%.

The biosimilar monoclonal antibodies market covered in this report is segmented by type into synthetic chemicals, biopharmaceuticals, others, by application into chronic & autoimmune diseases, oncology, others, and by compound into Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab.

Major players in the biosimilar monoclonal antibodies market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, and Intas Pharmaceuticals Limited.

[Biosimilar Monoclonal Antibodies Global Market Report 2021](#): COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides biosimilar MABs market overview, forecast biosimilar MABs market size and growth for the whole market, biosimilar MABs market segments, and geographies, biosimilar MABs market trends, biosimilar MABs market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Biosimilar Monoclonal Antibodies Market Report:
<https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp>

Here Is A List Of Similar Reports By The Business Research Company:

Oral Biologics And Biosimilars Market - By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron `s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies - Global Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market>

Monoclonal Antibodies (MABs) Global Market Report 2021: COVID-19 Impact and Recovery to 2030

<https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-mabs-global->

[market-report](#)

Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

<https://www.thebusinessresearchcompany.com/report/conjugated-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change>

Biosimilar Therapeutic Peptides Global Market Report 2021: COVID-19 Growth And Change To 2030

<https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptides-global-market-report-2020-30-covid-19-growth-and-change>

Interested to know more about [The Business Research Company?](#)

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/539867923>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

